
The IPO allotment process for Capillary Technologies IPO is expected to be finalised today on November 19, 2025, and the shares will be listed on both NSE and BSE. The tentative listing date is set for November 21, 2025.
Capillary Technologies launched its ₹877.50 crore IPO on November 14, 2025. The bidding window for the public subscription closed yesterday on November 18, 2025. This Bengaluru-based SaaS company is known for providing AI-powered customer loyalty and engagement solutions.
Check Capillary Technologies IPO Allotment Status on NSE, BSE and the registrar’s website.
Capillary Technologies IPO was a book-built issue of ₹877.50 crore. The issue comprised a fresh issue of ₹345 crore and an offer for sale (OFS) of 0.92 crore shares aggregating to ₹532.50 crores by existing shareholders.
The IPO price band was set between ₹549 and ₹577 per share. The minimum lot size for an application was 25, with the minimum investment for retail investors being ₹14,425 based on the upper band.
JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), and Nomura Financial Advisory and Securities (India) Private Limited were the book-running lead managers to the issue. MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) was the registrar for the IPO.
[November 18, 2025, 6:20 PM]
Capillary Technologies saw an overall subscription of 52.98 times as per the NSE data as of November 18, 2025, 6:20 p.m.
The public issue was subscribed:
Explore other Upcoming IPOs on BSE and NSE.
The company plans to utilise the net proceeds from the fresh issue towards:
Check out newly Listed IPOs on BSE and NSE.
Capillary Technologies is a global SaaS leader in loyalty management, customer data platforms, and engagement automation. The company works with over 250 brands across 30+ countries and derives a major share of its revenue from international markets, particularly North America.
Financially, the company reported:
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here